ESMO 2016: PCCTC Study Benefits Men With Neuroendocrine Prostate Cancer
October 10, 2016 | Press Releases
The selective aurora A kinase inhibitor Alisertib may benefit some patients with neuroendocrine prostate cancer.
Committed to world-class science!
Our services translate scientific discoveries into improved standards of care, ensuring efficient trial selection, reporting, site management, clinical operations and data analyses.